194 related articles for article (PubMed ID: 30327236)
1. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J; De Ruysscher D; Sonke JJ; Damen E; Sikorska K; Reymen B; van Elmpt W; Westman G; Fredberg Persson G; Dieleman E; Bjorkestrand H; Faivre-Finn C; Belderbos J
Radiother Oncol; 2019 Feb; 131():166-173. PubMed ID: 30327236
[TBL] [Abstract][Full Text] [Related]
2. A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.
La Fontaine M; Vogel W; van Diessen J; van Elmpt W; Reymen B; Persson G; Westman G; De Ruysscher D; Belderbos J; Sonke JJ
Radiother Oncol; 2018 May; 127(2):259-266. PubMed ID: 29709378
[TBL] [Abstract][Full Text] [Related]
3. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
[TBL] [Abstract][Full Text] [Related]
4. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: practical implications of using a broad or sharp brush.
Meijer G; Steenhuijsen J; Bal M; De Jaeger K; Schuring D; Theuws J
Radiother Oncol; 2011 Sep; 100(3):396-401. PubMed ID: 21955663
[TBL] [Abstract][Full Text] [Related]
5. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Møller DS; Nielsen TB; Brink C; Hoffmann L; Lutz CM; Drøgemüller Lund M; Hansen O; Schytte T; Khalil AA; Knap MM; Nyhus CH; Ottosson W; Sibolt P; Borissova S; Josipovic M; Persson G; Appelt AL
Radiother Oncol; 2017 Aug; 124(2):311-317. PubMed ID: 28688525
[TBL] [Abstract][Full Text] [Related]
7. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
8.
Cooke SA; de Ruysscher D; Reymen B; Lambrecht M; Fredberg Persson G; Faivre-Finn C; Dieleman EMT; Lewensohn R; van Diessen JNA; Sikorska K; Lalezari F; Vogel W; van Elmpt W; Damen EMF; Sonke JJ; Belderbos JSA
Radiother Oncol; 2023 Apr; 181():109492. PubMed ID: 36706958
[TBL] [Abstract][Full Text] [Related]
9. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
10. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
11. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.
Doyen J; Poudenx M; Gal J; Otto J; Guerder C; Naghavi AO; Gérard A; Leysalle A; Cohen C; Padovani B; Ianessi A; Schiappa R; Chamorey E; Bondiau PY
Radiother Oncol; 2018 May; 127(2):239-245. PubMed ID: 29650404
[TBL] [Abstract][Full Text] [Related]
13. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
[TBL] [Abstract][Full Text] [Related]
14. Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461).
Raman S; Bissonnette JP; Warner A; Le L; Bratman S; Leighl N; Bezjak A; Palma D; Schellenberg D; Sun A
Clin Lung Cancer; 2018 Sep; 19(5):e699-e703. PubMed ID: 29903551
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA; Belderbos JSA; Reymen B; Lambrecht M; Fredberg Persson G; Faivre-Finn C; Dieleman EMT; van Diessen JNA; Sonke JJ; de Ruysscher D
Radiother Oncol; 2024 Jul; 196():110312. PubMed ID: 38663582
[TBL] [Abstract][Full Text] [Related]
16. Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
Mac Manus MP; Ding Z; Hogg A; Herschtal A; Binns D; Ball DL; Hicks RJ
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1365-71. PubMed ID: 20675076
[TBL] [Abstract][Full Text] [Related]
17. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
[TBL] [Abstract][Full Text] [Related]
18. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
19. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.
Even AJ; van der Stoep J; Zegers CM; Reymen B; Troost EG; Lambin P; van Elmpt W
Radiother Oncol; 2015 Aug; 116(2):281-6. PubMed ID: 26238010
[TBL] [Abstract][Full Text] [Related]
20. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
